# Gufic Biosciences Ltd (GUFICBIO)
> Exchange: NSE | Sector: Pharma | ISIN: INE742B01025

## Price
Current Price: ₹293.7
Day Change: +1.73%
52W High: ₹407.85
52W Low: ₹268
Market Cap: ₹2,779 Cr

## Valuation
P/E: 55.53
P/B: 4.4
EPS: ₹4.99
Book Value: ₹63.02
Dividend Yield: 0%

## Returns
1Y Return: -7.17%

## Profitability
ROE: 0%
ROCE: 15.61%
Debt/Equity: 0.58
Revenue Growth: 11.4%
Profit Growth: -35.8%
EBITDA Margin: 13.36%
Operating Margin: 10.93%

## About
Gufic Biosciences Ltd is a Drug Manufacturers - Specialty & Generic company listed on NSE. The page combines exchange quotes, financial statements, shareholding, filings, and news so investors can review the business in one place.
Sector: Pharma
Industry: Drug Manufacturers - Specialty & Generic
Sub Industry: Unknown

## Business Model
Overview: Gufic Biosciences Ltd makes money through Domestic formulations, Exports and regulated markets, Specialty or institutional sales in Drug Manufacturers - Specialty & Generic. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Source: Derived from stock data
Revenue Streams:
- Domestic formulations
- Exports and regulated markets
- Specialty or institutional sales
Operating Model:
- Develops, manufactures, distributes, or services healthcare products across regulated channels.
- Approvals, product mix, compliance quality, and R&D productivity shape growth.
Recent Context:
- Announcement: Update On Further Investment In Selvax Pty Ltd.
- Announcement: Announcement under Regulation 30 (LODR)-Newspaper Publication
- BSE Filing: Update On Further Investment In Selvax Pty Ltd.

## Data Freshness
Quote Updated: 2026-05-24T20:00:11.526Z
Price History Updated: 2026-05-25T05:31:29.537Z
Latest Price History Date: 2026-05-24
Technicals Updated: 2026-05-25T05:31:29.537Z
Quant Updated: 2026-05-25T05:31:29.537Z
Sentiment Updated: 2026-05-25T05:31:29.537Z
Financials Status: current
Financials Updated: 2026-05-18T15:31:42.514Z
Financials Last Attempt: 2026-05-18T15:31:42.514Z
Financials Provider Tried: yahoo
Latest P&L Period: FY25
Latest Balance Sheet Period: FY25
Latest Cash Flow Period: FY25

## P&L (Mar 2025)
Revenue: ₹807 Cr
Operating Profit: ₹150 Cr (OPM 19%)
Net Profit: ₹86 Cr
Tax: ₹116 Cr

## Annual P&L History
Mar 2025: Rev ₹807Cr | PAT ₹86Cr | OPM 19%
TTM: Rev ₹820Cr | PAT ₹70Cr | OPM 17%

## Balance Sheet (Mar 2025)
Total Assets: ₹1093 Cr
Total Liabilities: ₹1093 Cr
Borrowings: ₹333 Cr
Cash: ₹undefined Cr

## Shareholding
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%

## Board
- Jayesh Pannalal Choksi, Chairman & MD
- Pranav Jayesh Choksi, CEO & Whole Time Director
- Pankaj Jayakumar Gandhi, Whole-Time Director
- Devkinandan B. Roonghta, Chief Financial Officer
- Nagesh  Yarrabathina, Chief Operating Officer

---
Source: rupiya.io/stocks/guficbio
Disclaimer: For research and education only. Not investment advice.